<DOC>
	<DOCNO>NCT00179725</DOCNO>
	<brief_summary>Phase I determine MTD evaluate safety profile oral lenalidomide day 1-21 give liposomal doxorubicin day 1 every 28 day cycle Phase II commence MTD establish , additional subject enrol receive oral lenalidomide day 1-21 liposomal doxorubicinon day 1 28 day cycle disease progression document .</brief_summary>
	<brief_title>Phase I/II Open-Label , Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Lenalidomide ( RevlimidÂ® CC-5013 ) With Liposomal Doxorubicin In Subjects With Advanced Ovarian Primary Peritoneal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>1 . Subjects must understand voluntarily sign informed consent document . 2 . Age &gt; = 18 year time signing informed consent form . 3 . Subjects must able adhere study visit schedule protocol requirement . 4 . Histological cytological documentation advance ovarian primary peritoneal carcinoma . 5 . Radiographic clinical evidence measurable metastatic advance ovarian primary peritoneal carcinoma . Subjects must measurable disease least 2 cm diameter . 6 . Subjects must treat progress follow chemotherapy include platinum paclitaxel . 7 . ECOG performance status 0 1 ( Appendix I : ECOG Performance Status Scale ) . 8 . Must 2d Echocardiogram/MUGA indicate LVEF institutional low limit normal within 42 day prior first dose study drug . 1 . Any following laboratory abnormality : 1 . Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm3 ( 1.5 x 109/L ) 2 . Platelet count &lt; 100,000 cells/mm3 ( 100 x 109/L ) 3 . Serum creatinine &gt; 2.5 mg/dL ( 221 mmol/L ) 4 . Serum SGOT/AST SGPT/ALT &gt; 3.0 x upper limit normal ( ULN ) 5 . Serum total bilirubin &gt; 1.2 mg/dL ( 20 mmol/L ) 2 . Any serious medical condition psychiatric illness place subject unacceptable risk study participation would prevent subject signing informed consent . 3 . Prior history malignancy ( except basal cell squamous cell carcinoma carcinoma situ breast ) unless subject free disease &gt; = 1 year . 4 . Known brain leptomeningeal disease ( CT scan MRI brain required case clinical suspicion central nervous system involvement ) . 5 . More 1 prior chemotherapy regimen . However , subject platinum sensitive disease ( i.e. , subject fail platinum contain regimen least six month complete regimen ) retreat platinum contain regimen eligible . 6 . Concurrent use anticancer agent . 7 . Any prior use Lenalidomide . 8 . Prior &gt; = grade 3 ( see Appendix III ) allergic reaction/hypersensitivity thalidomide . 9 . Prior &gt; = grade 3 ( see Appendix III ) rash desquamating ( blister ) rash take thalidomide . 10 . Use standard experimental anticancer drug therapy within 28 day initiation study drug therapy . 11 . History cardiac disease , New York Heart Association Class II great ( see Appendix V ) . 12 . Subjects receive &gt; 200mg/m2 anthracycline anthracendione either alone combination . ( Additional caution must take subject mediastinal radiation . )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>cc-5013</keyword>
	<keyword>revlimid</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>celgene</keyword>
</DOC>